Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.

Executive Summary

GlaxoSmithKline's Ariflo needs long-term efficacy studies to confirm the PDE-4 inhibitor's maintenance of effect in chronic obstructive pulmonary disease, an FDA advisory committee agreed Sept. 5

You may also be interested in...



Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot

The privately held European pharma is looking for a U.S. partner to commercialize the potentially first-in-class PDE4 inhibitor.

GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products

GlaxoSmithKline's pending chronic obstructive pulmonary disease therapy Ariflo (cilomilast) is among a dozen products manufactured in Cidra, Puerto Rico cited in recent FDA "Form 483" reports

GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products

GlaxoSmithKline's pending chronic obstructive pulmonary disease therapy Ariflo (cilomilast) is among a dozen products manufactured in Cidra, Puerto Rico cited in recent FDA "Form 483" reports

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel